← Human Trials & Peer-Reviewed Studies
Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial.
Plain-language guide to PMID 22316314 (2012): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, multiple sclerosis.
Key Facts
- PMID
- 22316314
- Journal
- Trials
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Dörr J et al. (4 authors)
- DOI
- 10.1186/1745-6215-13-15
- Registered trial
- NCT01440062
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis, published as a randomized controlled trial.
Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system in young adults.
How the Study Was Run
In design terms this was a randomized, double-blind and pilot study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
The EVIDIMS trial is a German multi-center, stratified, randomized, controlled and double-blind clinical phase II pilot study.
The primary outcome measure is the number of new lesions detected on T2-weighted cranial MRI at 3 tesla.
Secondary endpoints include additional magnetic resonance imaging and optical coherence tomography parameters for neuroinflammation and -degeneration, clinical parameters for disease activity, as well as cognition, fatigue, depression, and quality of life.
What Was Measured
PubMed files the paper under topics including Brain, Cholecalciferol, Dietary Supplements, Germany, Immunologic Factors, Interferon beta-1b and Interferon-beta.
What This Means in Plain Language
The paper is a randomized, double-blind and pilot study of Vitamin D, K2, Magnesium and Zinc in people with multiple sclerosis.
Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2012 (Trials), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.